1611473-89-2

Basic information

• Product Name: ethyl cis-4-(4-(((1S,2S)-2-(5-methoxypyridin-2-yl)cyclopropyl)methoxy)-2-methylpyrimidin-5-yl)cyclohexanecarboxylate
• Synonyms: ethyl cis-4-(4-(((1S,2S)-2-(5-methoxypyridin-2-yl)cyclopropyl)methoxy)-2-methylpyrimidin-5-yl)cyclohexanecarboxylate
• CAS NO: 1611473-89-2
• Molecular Weight: 425.528
• Mol File: 1611473-89-2.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: ethyl cis-4-(4-(((1S,2S)-2-(5-methoxypyridin-2-yl)cyclopropyl)methoxy)-2-methylpyrimidin-5-yl)cyclohexanecarboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: ethyl cis-4-(4-(((1S,2S)-2-(5-methoxypyridin-2-yl)cyclopropyl)methoxy)-2-methylpyrimidin-5-yl)cyclohexanecarboxylate(1611473-89-2)
• EPA Substance Registry System: ethyl cis-4-(4-(((1S,2S)-2-(5-methoxypyridin-2-yl)cyclopropyl)methoxy)-2-methylpyrimidin-5-yl)cyclohexanecarboxylate(1611473-89-2)

Safety Data

• Hazardous Substances Data: 1611473-89-2(Hazardous Substances Data)

Upstream product

• 1370527-96-0 ((1S,2S)-2-(5-methoxypyridin-2-yl)cyclopropyl)methanol 
• 1611453-26-9 ethyl 4-(4-chloro-2-methylpyrimidin-5-yl)cyclohexane-carboxylate 
• 1611453-25-8 ethyl 4-(4-hydroxy-2-methylpyrimidin-5-yl)cyclohexane-carboxylate 
• 1611453-24-7 ethyl 4-(4-hydroxy-2-methylpyrimidin-5-yl)cyclohex-3-ene-carboxylate 
• 1049004-32-1 (RS)-4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-cyclohex-3-enecarboxylic acid ethyl ester 
• 122948-57-6 ethyl 4-(((trifluoromethyl)sulfonyl)oxy)cyclohex-3-enecarboxylate 
• 17159-79-4 ethyl 4-oxocyclohexane-1-carboxylate 
• 1676-57-9 5-bromo-2-methylpyrimidin-4-ol 

Downstream Products

• 1611452-70-0 cis-4-(4-(((1S,2S)-2-(5-methoxypyridin-2-yl)cyclopropyl)methoxy)-2-methylpyrimidin-5-yl)cyclohexanecarboxylic acid 
• 1611452-71-1 cis-4-(4-(((1S,2S)-2-(5-methoxypyridin-2-yl)cyclopropyl)methoxy)-2-methylpyrimidin-5-yl)cyclohexanecarboxamide 

Relevant articles and documents

PYRIMIDINE PDE10 INHIBITORS

The present invention is directed to pyrimidine compounds which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 10 (PDE10). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.